98%
921
2 minutes
20
The intracellular loops that interlink the four transmembrane domains of Ca(2+)- and Na(+)-channels (Ca(v), Na(v)) have critical roles in numerous forms of channel regulation. In particular, the intracellular loop that joins repeats I and II (I-II loop) in high voltage-activated (HVA) Ca(2+) channels possesses the binding site for Ca(v)beta subunits and plays significant roles in channel function, including trafficking the alpha(1) subunits of HVA channels to the plasma membrane and channel gating. Although there is considerable divergence in the primary sequence of the I-II loop of Ca(v)1/Ca(v)2 HVA channels and Ca(v)3 LVA/T-type channels, evidence for a regulatory role of the I-II loop in T-channel function has recently emerged for Ca(v)3.2 channels. In order to provide a comprehensive view of the role this intracellular region may play in the gating and surface expression in Ca(v)3 channels, we have performed a structure-function analysis of the I-II loop in Ca(v)3.1 and Ca(v)3.3 channels using selective deletion mutants. Here we show the first 60 amino acids of the loop (post IS6) are involved in Ca(v)3.1 and Ca(v)3.3 channel gating and kinetics, which establishes a conserved property of this locus for all Ca(v)3 channels. In contrast to findings in Ca(v)3.2, deletion of the central region of the I-II loop in Ca(v)3.1 and Ca(v)3.3 yielded a modest increase (+30%) and a reduction (-30%) in current density and surface expression, respectively. These experiments enrich our understanding of the structural determinants involved in Ca(v)3 function by highlighting the unique role played by the intracellular I-II loop in Ca(v)3.2 channel trafficking, and illustrating the prominent role of the gating brake in setting the slow and distinctive slow activation kinetics of Ca(v)3.3.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2495038 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0002976 | PLOS |
Pharmaceuticals (Basel)
July 2025
Laboratory of Applied Chemistry and Environment (LCAE), Faculty of Science, University Mohammed Premier, Bd. Med VI B.P. 717, Oujda 60000, Morocco.
Oncogenic KRAS drives ~30% of solid tumours, yet the only approved G12C-specific drugs benefit ≈ 13% of KRAS-mutant patients, leaving a major clinical gap. We sought mutation-agnostic natural ligands from Ziziphus lotus, whose stereochemically rich phenolics may overcome this limitation by occupying the SI/II (Switch I/Switch II) groove and locking KRAS in its inactive state. Phytochemical mining yielded five recurrent phenolics, such as (+)-catechin, hyperin, astragalin, eriodictyol, and the prenylated benzoate amorfrutin A, benchmarked against the covalent inhibitor sotorasib.
View Article and Find Full Text PDFBioorg Chem
August 2025
State Key Laboratory Base of Eco-chemical Engineering, Qingdao Key Laboratory of Biomacromolecular Drug Discovery and Development, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, People's Republic of China. Electronic address:
The antibacterial mechanisms of macrolides primarily focus on ribosome inhibition, while their potential interactions with topoisomerases (Topo) remain to be thoroughly explored. In this study, novel tilmicosin (TIM) derivatives were designed and screened with strong binding affinities to Topo I/II by using molecular docking. Then, four TIM derivatives (T-1, T-2, T-16, and T-17) were selected as potential candidates for subsequent synthesis.
View Article and Find Full Text PDFBMC Pulm Med
July 2025
Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, No. 241, Huaihai West Road, Shanghai, 200030, China.
Background: EGFR mutations have been classified into four functional subgroups (Classical-like, P-loop and αC-helical compressing (PACC), T790M-like, and exon 20 loop insertions) based on their influence on EGFR protein structure, as well as response to various types of EGFR-tyrosine kinase inhibitors (TKIs). However, the differences in molecular phenotypes and clinical outcomes for patients carrying these different forms of EGFR mutations are not fully understood. Here we sought to investigate the distribution of different EGFR structural types in Chinese NSCLC patients and the biological characteristics of each subgroup.
View Article and Find Full Text PDFJ Transl Med
June 2025
State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, 300020, China.
Background: Chimeric antigen receptor (CAR) T-cell therapies targeting CD19 have demonstrated promising efficacy in treating refractory or relapsed B-cell malignancies. Nonetheless, challenges such as antigen escape-mediated relapse and toxicities, including cytokine release syndrome (CRS) and neurotoxicity, may impede their clinical application.
Methods: In this study, we developed a fully human, bivalent loop bi-CAR-T targeting both CD19 and CD22 (CT120).
Int Urogynecol J
May 2025
Department of Surgical Urology, the Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China.
Introduction And Hypothesis: The Cdk1/p53/p21 feedback loop could play an important role in maintaining a consistently high urinary tract epithelial permeability. This study is aimed at elucidating whether this feedback loop is associated with the inadequate autophagic response and the heightened inflammatory response in interstitial cystitis/bladder pain syndrome (IC/BPS).
Methods: To construct the IC/BPS cell model, HTB4 cells were first treated with 1% HO for 1 h, followed by a 24-h exposure to TNFα (10 ng/ml).